AI Test Doesn't Just Predict Kidney Disease—It Changes Its Course

NEW YORK, NY – June 30, 2026 – For years, the promise of precision medicine has been a tantalizing but often distant goal. Today, that goal snapped into focus. Renalytix, an AI-enabled diagnostics firm, unveiled landmark two-year results for its KidneyIntelX.dkd test, demonstrating for the first time that a prognostic tool can not only predict the path of diabetic kidney disease (DKD) but actively change its trajectory.

Published in the peer-reviewed journal Diabetes, Obesity and Metabolism, the study of 2,470 patients across two major U.S. health systems is a watershed moment. It provides the kind of robust, real-world evidence that business leaders and healthcare executives have been waiting for—proof that integrating advanced diagnostics into clinical operations can produce sustained, measurable improvements in patient health and system efficiency.

From Prognosis to Active Intervention

The standard approach to managing early-stage chronic kidney disease has long been a waiting game, guided by imprecise markers like eGFR (estimated glomerular filtration rate) and UACR (urine albumin-to-creatinine ratio). Clinicians knew many patients with diabetes were on a path to kidney failure, but identifying the highest-risk individuals early enough to intervene decisively was a challenge. KidneyIntelX.dkd was designed to solve this, combining blood-based biomarkers with clinical data and an AI algorithm to generate a highly accurate risk score.

But the two-year data proves the test is far more than a crystal ball. It has become a catalyst for action. The study, conducted at Mount Sinai Health System and Wake Forest/Atrium Health, shows that when clinicians are armed with a clear, color-coded risk assessment, they change their behavior. Use of guideline-recommended therapies like SGLT2 inhibitors and GLP-1 receptor agonists surged, particularly in the highest-risk patients. At Mount Sinai, SGLT2i use in the high-risk group soared to 70%, while combination therapy with GLP-1 RAs nearly tripled from 12% to 32% over the same period.

"These two-year data provide the clearest real-world picture yet of what risk stratification can do when applied consistently at scale," said Dr. David Lam, a co-principal investigator and endocrinologist with the Mount Sinai Health System. "What we see is that a structured, biomarker-guided approach to prescribing translates into targeted therapy decisions — higher-risk patients receiving more intensive treatment, and lower-risk patients largely spared unnecessary escalation. That is what precision medicine is supposed to look like in practice."

The results are not just correlational; they demonstrate a causal link. Patients who initiated these modern therapies after their test had nearly double the odds of seeing their risk score improve over time. This is the holy grail of diagnostics: a tool that doesn't just inform but directly enables and validates therapeutic intervention. The data shows that 29% of patients who were retested moved into a lower risk category, a shift linked to measurable drops in key biomarkers like KIM-1 (Kidney Injury Molecule-1). The test, therefore, is not a one-time snapshot but a dynamic, longitudinal tool for managing care.

The Human and Health System Impact

Beyond the clinical metrics, the implications for patients and the broader healthcare system are profound. For the 15 million Americans with DKD, this represents a new form of hope. The study found that in high-risk patients, the rate of kidney function decline (eGFR slope) improved by an astounding 43% over two years, while albuminuria (UACR), a key marker of kidney damage, fell by 23%. These aren't just numbers; they represent more years of life free from the specter of dialysis or a kidney transplant.

From a systems perspective, this is the kind of disruptive innovation that can bend the cost curve. Diabetic kidney disease is a primary driver of healthcare spending, with Medicare alone spending an estimated $85 billion annually on early-stage CKD care. The end stages are even more costly. By identifying patients at highest risk—those 10.4 times more likely to experience kidney failure, according to the study—and intervening early, the potential for savings is immense.

Prior economic analyses of KidneyIntelX have projected that its adoption could save a payer system over $1 billion for every 100,000 patients tested over five years, with a breakeven point occurring in less than two years. These savings are realized through slowed disease progression and the avoidance of catastrophic events like dialysis crashes. The new two-year clinical data provides the strongest validation yet for these economic models, making a compelling case for widespread adoption by health systems and payers.

Validating a New Market with Real-World Proof

For Renalytix, this study is a commercial and strategic triumph. In the high-stakes world of medical diagnostics, securing both FDA approval and Medicare reimbursement is a monumental achievement. KidneyIntelX.dkd is the only prognostic test for early-stage DKD to have cleared both hurdles, giving it a commanding market position. However, the ultimate key to commercial success is demonstrating real-world utility that drives adoption.

This study delivers that proof in spades. By partnering with major health systems and embedding its test into actual clinical workflows, the company has generated evidence that is far more persuasive to hospital administrators and insurers than data from a controlled clinical trial alone. This real-world validation, which has spurred partnerships with data giants like Tempus AI and driven deeper EHR integrations for "one-click" ordering, is the foundation of the company's growth strategy.

Investors have taken note, with the company's stock surging on the news. The results reinforce the company's revenue projections, which anticipate growth from $8.4 million in fiscal year 2026 to $42.0 million in 2028. With a reimbursement rate of $950 per test from Medicare, even capturing a small fraction of the vast DKD market represents a multi-billion dollar opportunity.

"From a nephrology standpoint, what matters most is whether risk stratification translates into durable kidney protection — and that is what we are seeing here," commented Dr. Joji Tokita, a nephrologist at Mount Sinai and co-principal investigator. The sustained attenuation in eGFR decline and the ability to track risk reduction via retesting provides clinicians with a powerful feedback loop to guide and adjust patient care over the long term.

This landmark study does more than just validate a single diagnostic test. It provides a blueprint for the future of chronic disease management, where AI-powered insights are seamlessly integrated into care pathways to identify risk, guide therapy, and deliver objectively better outcomes. It is a clear signal that the next industrial revolution in healthcare is not just coming; for patients with diabetic kidney disease, it has already begun.